Clinical Trial: Evaluating the Ability of Zoledronic Acid to Reduce the Rate of Subsequent Osteoporotic Fractures After a Hip Fracture

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title:

Brief Summary: The purpose of this study is to evaluate whether zoledronic acid given once yearly for two years to men and women after surgical repair of a recent hip fracture will significantly reduce the rate of all re-occurring (new) osteoporotic fractures. All patients will receive vitamin D and calcium.

Detailed Summary:
Sponsor: Novartis Pharmaceuticals

Current Primary Outcome: Significant reduction in rate of clinical fractures after surgical repair of hip fracture

Original Primary Outcome:

Current Secondary Outcome: Increase in total hip and femoral neck BMDs

Original Secondary Outcome:

Information By: Novartis

Dates:
Date Received: September 24, 2002
Date Started: February 2002
Date Completion:
Last Updated: May 1, 2012
Last Verified: May 2012